PETMED EXPRESS, INC. (PETS) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 0.58%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | 0.58% | Share-based compensation / revenue. Period ending 2026-06-30. $972.00K ÷ $168.86M × 100 ≈ 0.58% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | |
| Revenue | 168.86M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 972.00K USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -30.77M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $168.86M | $972.00K | $-30.77M | (m) | (m) | 0.58% | (m) | (m) |
| 2026-03-31 | (m) | $179.02M | $1.36M | $-58.67M | (m) | (m) | 0.76% | (m) | (m) |
| 2025-12-31 | (m) | $186.96M | $1.69M | $-59.00M | (m) | (m) | 0.90% | (m) | (m) |
| 2025-09-30 | (m) | $198.26M | $1.88M | $-48.98M | (m) | (m) | 0.95% | (m) | (m) |
| 2025-06-30 | (m) | $211.94M | $2.21M | $-40.05M | (m) | (m) | 1.04% | (m) | (m) |
| 2025-03-31 | (m) | $226.97M | $-6.59M | $-1.53M | (m) | (m) | -2.90% | (m) | (m) |
| 2024-12-31 | (m) | (m) | $-5.51M | $655.00K | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | (m) | $-4.25M | $-1.97M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | (m) | $-3.10M | $-1.65M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | (m) | $6.87M | $-8.16M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | (m) | $6.83M | $-4.54M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | (m) | $6.89M | $-10.45M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | (m) | $6.84M | $-7.05M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | (m) | $6.62M | $-1.43M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | (m) | $6.50M | $12.74M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | (m) | $6.17M | $18.66M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | (m) | $5.37M | $23.78M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | (m) | $4.55M | $25.71M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | (m) | $4.05M | $27.04M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | (m) | $3.39M | $31.19M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | $3.29M | $33.57M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | $3.31M | $37.59M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | $3.04M | $37.71M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | (m) | $2.97M | $36.35M | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | $2.93M | $34.25M | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | $284.13M | $2.82M | $30.98M | (m) | (m) | 0.99% | (m) | (m) |
| 2019-12-31 | (m) | (m) | $2.87M | $30.27M | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | (m) | $2.96M | $31.75M | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | $3.01M | $36.58M | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | $283.42M | $3.10M | $46.17M | (m) | (m) | 1.09% | (m) | (m) |
| 2018-12-31 | (m) | (m) | $3.03M | $52.38M | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | (m) | $2.93M | $54.43M | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | $2.80M | $53.48M | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | $273.80M | $2.58M | $52.14M | (m) | (m) | 0.94% | (m) | (m) |
| 2017-12-31 | (m) | (m) | $2.35M | $49.83M | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | (m) | $2.13M | $46.02M | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | $1.97M | $41.50M | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | (m) | $1.94M | $37.48M | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | (m) | $1.87M | $34.37M | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | (m) | (m) | $1.78M | $34.34M | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | (m) | $1.70M | $33.70M | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | (m) | $1.61M | $32.39M | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | (m) | $1.55M | $31.62M | (m) | (m) | (m) | (m) | (m) |
| 2015-09-30 | (m) | (m) | $1.50M | $31.67M | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | $1.48M | $28.87M | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | (m) | $1.48M | $27.61M | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | (m) | $1.49M | $26.93M | (m) | (m) | (m) | (m) | (m) |
| 2014-09-30 | (m) | (m) | $1.50M | $26.32M | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | $1.49M | $28.56M | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | $1.48M | $28.22M | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | (m) | $1.55M | $28.34M | (m) | (m) | (m) | (m) | (m) |
| 2013-09-30 | (m) | (m) | $1.64M | $28.50M | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | $1.75M | $28.30M | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | (m) | $1.94M | $27.00M | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | (m) | $2.06M | $26.01M | (m) | (m) | (m) | (m) | (m) |
| 2012-09-30 | (m) | (m) | $2.16M | $24.91M | (m) | (m) | (m) | (m) | (m) |
| 2012-06-30 | (m) | (m) | $2.23M | $24.66M | (m) | (m) | (m) | (m) | (m) |
| 2012-03-31 | (m) | (m) | $2.25M | $26.02M | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | $2.17M | $33.02M | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-03-31 | (m) | (m) | $1.59M | $40.54M | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CVS HEALTH Corp (CVS) | United States | $108.783B | 27.06 |